Acipimox inhibits human carbonic anhydrases

Mattia Moria and Claudia T. Supuranb

aDepartment of Biotechnology, Chemistry and Pharmacy, “Department of Excellence 2018-2022”, University of Siena, Siena, Italy; bNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy

ABSTRACT

Acipimox (Olbetam) is a clinically used drug for the treatment of hyperlipidaemic patients that do not respond to other therapeutic regimens. The drug exerts its hypolipidemic effect by inhibiting lipolysis as well as the fatty acid flux to the liver, by reducing the precursor pool size of very low density lipoprotein (VLDL)-triglyceride and inhibiting VLDL synthesis, with the consequent reduction of plasma triglyceride levels and increase of high density lipoprotein (HDL) cholesterol. The drug also interferes with peroxisomal oxidative activities and enhances autophagy, and for such reasons it was proposed as one of the first therapeutic agents for healthy ageing by Bergamini’s group. It is known that autophagy plays a crucial role in cell housekeeping processes during fasting, contributing to the removal of altered membranes, mitochondria, as well as other organelles, including peroxisomes, which may explain the antiaging effects of caloric restriction, which in turn can be enhanced by using anti-lipolytic drugs such as acipimox at dosages lower than those used for the treatment of hyperlipidaemia.

1. Introduction

Acipimox (Olbetam) is a clinically used drug for the treatment of hyperlipidaemic patients that do not respond to other therapeutic regimens. The drug exerts its hypolipidemic effect by inhibiting lipolysis as well as the fatty acid flux to the liver, by reducing the precursor pool size of very low density lipoprotein (VLDL)-triglyceride and inhibiting VLDL synthesis, with the consequent reduction of plasma triglyceride levels and increase of high density lipoprotein (HDL) cholesterol. The drug also interferes with peroxisomal oxidative activities and enhances autophagy, and for such reasons it was proposed as one of the first therapeutic agents for healthy ageing by Bergamini’s group. It is known that autophagy plays a crucial role in cell housekeeping processes during fasting, contributing to the removal of altered membranes, mitochondria, as well as other organelles, including peroxisomes, which may explain the antiaging effects of caloric restriction, which in turn can be enhanced by using anti-lipolytic drugs such as acipimox at dosages lower than those used for the treatment of hyperlipidaemia.

Carboxylates constitute one of the most versatile classes of carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs)5-7. Kinetic, crystallographic, computational and other biophysical studies evidenced a multitude of possibilities by which carboxylates inhibit these enzymes, among which direct coordination to the metal ion, anchoring to the metal ion-coordinated water molecule, occlusion of the active site entrance or even binding outside the active site cavity in a hydrophobic pocket adjacent to the entrance to the catalytic site8-10. Various classes of aliphatic, aromatic, and heterocyclic carboxylates were investigated in detail as CAIs in the last decades11-10 and many such compounds showed significant inhibitory action and selectivity against the many catalytically active CA isoforms (of the 15 presently known), some of which are involved in crucial physiological or pathological phenomena11. Although no carboxylate CAI is in clinical use at this moment, sulphonamides, sulfamates or sulfamides with such an action are widely employed for the treatment of many diseases, among which edoema, glaucoma, epilepsy, obesity, hypoxic tumours, etc.6-8, whereas other such compounds are under investigation for the management of cerebral ischaemia, neuropathic pain or arthritis13. Recently, we have examined carboxylate 2, which is structurally similar to acipimox 1 as a CAI, finding that it acts as a weak inhibitor of several human isoforms. We thus decided to investigate whether acipimox possesses such an activity and investigated in detail its interaction with all catalytically active human isoforms (hCA I–XIV) by means of kinetic and computational studies.

2. Materials and methods

2.1. Computational studies

The crystallographic structures of hCAs available in the Protein Data Bank (PDB) were retrieved under the following accession codes, and used as rigid receptors in molecular docking simulations: hCA I (PDB-ID: 6I0J)14, hCA II (PDB-ID: 3K34)15, hCA III (PDB-ID: 2HF)16, hCA IV (PDB-ID: 3FW3)17, hCA VI (PDB-ID: 3FE4)18, hCA VII (PDB-ID: 6H3B)19, hCA IX (PDB-ID: 5FL4)20, hCA XII (PDB-ID: 1JDO)21, hCA XIII (PDB-ID: 3CZV)22, hCA XIV (SCJF)23. For hCAs structures in complex with covalent Zn(II) binders, the Zn(II)-bound water molecule was modelled as described previously7. Atomic RESP charges of acipimox were computed at the HF/6-311G* level of theory using Gaussian 16 rev. C.01c24. Molecular docking was carried out with the GOLD program (The Cambridge Crystallographic Data Centre) version 202025,26, by centreing a spherical binding site having a radius of 14 Å on the catalytic Zn(II) ion. During docking, the Zn(II)-bound water molecule was handled by the “toggle” function of the GOLD program. The CHEMPLP docking function was used for docking and scoring.
purposes. Docking complexes between acipimox and hCA IX were relaxed through molecular dynamics (MD) simulations carried out with AMBER18. The ff14SB force field was used to parametrise the protein, while the ligand was parametrised with the General Amber Force Field (GAFF) using the RESP partial atomic charges. Each complex was solvated in a rectangular box of TIP3P-type water molecules buffering 6 Å from the protein. Na\(^+\) counter-ions were added to neutralise the total charge of the system. The bound approach was used to parametrise the catalytic Zn(II) ion, to which an arbitrary charge of +1 was assigned based on a previous work. The protocol already described elsewhere was used to run MD simulations. In brief, the solvent was first energy minimised for 500 steps using the steepest descent algorithm (SD) followed by 2500 steps with the conjugate gradient algorithm (CG) while keeping the solute as frozen. The solvated solute was then energy minimised for 1000 steps with the SD and subsequent 5000 steps with the CG before heating to 300 K for 1 ns using the Langevin thermostat. The system's density was equilibrated for 1 ns by the Berendsen barostat, then the system was preliminarily equilibrated for 50 ns before running the final production of MD trajectories for 150 ns. A time-step of 2 fs was used. Three independent MD replicas were run for each acipimox/hCA IX docking complex. Analysis of MD trajectories was carried out with the CPPTRAJ software.

### 2.2. Carbonic anhydrase inhibition

The CA-catalysed CO\(_2\) hydration activity has been measured with an Applied Photophysics stopped-flow instrument. The used pH indicator was phenol red (at a concentration of 0.2 mM), working at the absorbance maximum of 557 nm. 10 mM HEPES (pH 7.4) was employed as a buffer, in the presence of 10 mM NaClO\(_4\) to maintain the ionic strength constant. The initial rates of the CA-catalysed CO\(_2\) hydration reaction were followed up for a period of 10 to 100 s. The substrate CO\(_2\) concentrations ranged from 1.7 to 17 mM for determining the inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction were used to determine the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10 mM) were prepared in distilled-deionized water with maximal 5% DMSO, and dilutions up to 10 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min prior to the assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by nonlinear least-squares methods using Prism 3 and the Cheng-Prusoff equation, as reported previously, and represent the mean from at least three different determinations. The hCAs concentration in the assay system were of 5.3–15.8 nM. All human enzymes were recombinant proteins obtained in-house, as described earlier.

#### 2.3. Chemicals

Acipimox, acetazolamide, buffers and other reagents were the highest purity compounds available from Sigma-Aldrich (Milan, Italy).

### 3. Results

#### 3.1. CA inhibition

Acipimox 1 was tested for the inhibition of all catalytically active human CA isoforms, hCA I – XIV by using a stopped-flow CO\(_2\) hydrase assay (Table 1). Compound 2, structurally related to acipimox, and acetazolamide 3, a standard sulphonamide CAI were also included in Table 1 for comparison reason, as their inhibition profile was determined in the same manner as for 1.

Data from Table 1 show that acipimox is an effective micromolar inhibitor of all CA isoforms (K\(_i\)s in the range of 2.8–9.2 \(\mu\)M) except hCA XIII for which the inhibition constant is an order of magnitude higher, i.e. 87 \(\mu\)M. The isoforms which were more effectively inhibited by acipimox were hCA VB and hCA I, with K\(_i\)s of 2.8 and 3.3 \(\mu\)M, respectively. Although the structurally related compound 2 was tested only on a limited number of isoforms, it seems to be much less effective compared to acipimox as a CAI (Table 1). On the other hand, the sulfonamide inhibitor 3 is highly effective against all isoforms except hCA III, but this is a well understood phenomenon which has been discussed in details elsewhere.

| hCA | Acipimox (K\(_i\)) | Acetazolamide (K\(_i\)) | 
|-----|------------------|-----------------------|
| hCA I | 3.3 \(\mu\)M | 72 \(\mu\)M |
| hCA II | 7.5 \(\mu\)M | >100 \(\mu\)M |
| hCA III | 5.4 \(\mu\)M | >100 \(\mu\)M |
| hCA IV | 8.8 \(\mu\)M | >100 \(\mu\)M |
| hCA VA | 7.5 \(\mu\)M | NT |
| hCA VB | 2.8 \(\mu\)M | NT |
| hCA VI | 7.0 \(\mu\)M | NT |
| hCA VII | 9.2 \(\mu\)M | NT |
| hCA IX | 6.3 \(\mu\)M | NT |
| hCA XII | 8.4 \(\mu\)M | NT |
| hCA XIII | 87 \(\mu\)M | NT |
| hCA XIV | 5.9 \(\mu\)M | NT |

*Mean from 3 different assays, by a stopped flow technique (errors were in the range of ±5–10% of the reported values, data not shown). NT: not tested.

*From ref. [8].
3.2. Computational studies

The possible interaction between acipimox and hCAs was investigated by molecular docking and MD simulations. While docking is a highly powerful tool to rapidly predict the possible ligand binding mode and score towards a macromolecular target, MD simulations are more time-demanding calculations that explore the conformational and energy evolution of a molecular system in physiological conditions over the time. First, the RESP atomic partial charges of acipimox were computed at the HF/6-311G* level of theory, and used in subsequent molecular simulations. Molecular docking was carried out against hCAs investigated in this work, for which the structure has been elucidated preferentially by X-ray crystallography and NMR spectroscopy, and is available in public repositories such as for instance the PDB. This choice did not allow to predict the binding mode of acipimox against hCA VA and VB isoforms. Given the multiple binding modes of acipimox pharmacophores to hCAs, as underlined in several recent reviews and works here we carried out docking simulations by considering the Zn(II)-bound water molecule as explicit or by removing it. As expected, the binding mode and score of acipimox is significantly different in the two scenarios. In docking to hCAs having the Zn(II)-bound water molecule (Figure 1), acipimox mostly interacts with the water molecule by H-bond interactions established by the N-oxide group. This interaction pattern was observed in the docking pose of acipimox against hCA I, hCA IV, hCA IX, and hCA XII-XIV (Figure 1(A,D,G-L)). In these docking poses, the carboxylic group projects towards the entrance of the catalytic site, where it interacts with Asn, Gln or Ser residues also thanks to the possible cooperation of the pyrazine N atom. Docking against hCA II and hCA VII shows the aromatic N atom binding to the Zn(II)-bound water molecule (Figure 1(B,F)), while only in the case of hCA VII the water molecule is anchored by the carboxylic group (Figure 1(E)). Docking against hCA III...
shows a peculiar binding mode, i.e. acipimox is unable to bind the water molecules but seems to occlude the catalytic site of the enzyme (Figure 1(C)). Overall, when the water molecule coordinated to the catalytic Zn(II) ion is considered explicitly, acipimox can potentially adopt different binding modes within the highly conserved active site of hCAs. In contrast, when docking simulations were carried against hCAs that do not bear the water molecule within the Zn(II) coordination system, a very consistent binding mode of acipimox was obtained (Figure 2). Specifically, the catalytic Zn(II) ion is coordinated to the carboxylate group, which also contacts a Thr residue by H-bond interactions. The N-oxide group is H-bonded to the proton shuttle His residue in hCA I (Figure 2(A–I)) and to Thr or Gln residues in other isoforms but

Table 2. GOLD CHEMPLP scores of acipimox against a panel of hCAs.

|                | CHEMPLP score | Catalytic Zn(II) ion |
|----------------|---------------|---------------------|
| Zn(II)-bound water molecule |               |                     |
| hCA I          | 37.45         | 53.12               |
| hCA II         | 41.23         | 53.74               |
| hCA III        | 44.37         | 52.31               |
| hCA IV         | 47.85         | 51.76               |
| hCA VI         | 43.13         | 55.62               |
| hCA VII        | 46.43         | 54.73               |
| hCA IX         | 46.90         | 59.75               |
| hCA XII        | 46.61         | 53.17               |
| hCA XIII       | 46.13         | 53.83               |
| hCA XIV        | 46.36         | 55.83               |

Figure 2. Predicted binding mode of acipimox against the crystallographic structure of hCAs in which the Zn(II)-bound water molecule was not considered in docking simulations. A) hCA I; B) hCA II; C) hCA III; D) hCA IV; E) hCA VI; F) hCA VII; G) hCA IX; H) hCA XII; I) hCA XIII; L) hCA XIV. hCAs are shown as green cartoon, residues within 5 Å from acipimox are shown as green lines. Acipimox is shown as cyan sticks, the catalytic Zn(II) ion as a grey sphere. Polar interactions are highlighted by black dashed lines.
hCA VI and hCA XII-XIV. Only in hCA IX and hCA XII, the pyrazine N atom is H-bonded to a Thr residue (Figure 2(G–L)). Notably, comparison of docking scores sharply highlights the tighter binding of acipimox to the catalytic Zn(II) ion than the Zn(II)-coordinated water molecule (Table 2), also showing a homogeneous distribution of theoretical affinity values that is in agreement with experimental results.

Overall, docking simulations suggest that acipimox is able to fit the active site of a panel of hCAs, and that it binds preferentially to the catalytic Zn(II) ion rather than the Zn(II)-coordinated water molecule.

To further corroborate the binding hypothesis emerged by docking analysis, MD simulations were carried out on docking complexes between acipimox and hCA IX, which was selected as a case study due to its role as a drug target in anticancer therapy. Three replicas of 150 ns of MD simulations were run, for a total simulation time of 450 ns on each acipimox/hCA IX complex. Results clearly show that the interaction between acipimox and the Zn(II) bound water molecule is unstable in every replica, as underlined by the analysis of the root mean square deviation (RMSD) of active site residues and acipimox, as well as by the distance plots between the zinc-binding group of acipimox in the two poses and the catalytic Zn(II) ion (Figure 3). In fact, starting from the docking pose in which acipimox is H-bonded to the Zn(II)-coordinated water molecule (Figure 1(G)), in every replica the compound detaches from the active site of the enzyme and moves into the bulk solvent (Figure 3(A,C)). In a single replica (see black line in Figure 3(C)), acipimox interacts in a site of CA IX that was already characterised in hCAs for the interaction of small molecules, although this is a transient interaction in MD simulations.

In contrast, the direct binding of acipimox to the catalytic Zn(II) ion is much more stable and persistent in time, as observed in two MD replicas (Figure 3(D), red and green line). In one of these latter, a conformational switch of acipimox is observed (Figure 3(D), green line), whereas in the third replica acipimox is extruded from the hCA IX active site after around 90 ns of MD simulations (Figure 3(D), black line). A representative MD frame was extracted from each MD replica by cluster analysis carried out on acipimox and residues of the hCA IX active site. Visual inspection of representative frames clearly highlights a highly consistent binding mode of acipimox in the three replicas (Figure 4). The compound interacts with the catalytic Zn(II) ion and with Thr201 through a water-bridged H-bond, while additional water-bridged interactions are established with Gln residues near the entrance of the active site (Figure 4(A,B)).

4. Conclusions

We demonstrate here that acipimox, a clinically used drug for the treatment of hyperlipidaemia, is also an effective, micromolar inhibitor of all human CA isoforms except hCA XIII for which the inhibitory effects were weak. Being a carboxylic acid derivative, and as we were unable to resolve the X-ray crystal structure of an
adduct of any CA isoform with this drug, we employed computational techniques for understanding its inhibition mechanism. Docking results were corroborated by MD simulations, clearly showing that acipimox preferentially binds directly the catalytic Zn(II) ion of hCAs in a monodentate fashion with an oxygen atom from the carboxylate zinc-binding group. Furthermore, the binding of the drug to the Zn(II)-coordinated water molecule was shown to be less stable and persistent in time. The interactions established by acipimox within the hCAs active site are nicely overlapping with those observed for compounds having similar pharmacophores (COO\(^-\) as zinc-binding group), which may thus shed further light on the ability of this small molecular drug to inhibit hCAs. As acipimox interferes with the lipid metabolism, and since some CAIs are used for the treatment and prevention of obesity\(^1\), these data may be useful for the design of more effective carboxylate CAIs with pharmacological applications.

**Acknowledgements**

MM thanks Prof. Adalgisa Sinicropi (University of Siena) for granting access to the use of Gaussian 16. We are grateful to Dr. Alfonso Maresca for technical assistance.

**Disclosure statement**

CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**Funding**

This research was financed by the Italian Ministry for Education and Science (MIUR), grant PRIN: rot. 2017XYBP2R and by Ente Cassa di Risparmio di Firenze (ECRF), grant CRF2020.1395.

**ORCID**

Mattia Mori [http://orcid.org/0000-0003-2398-1254](http://orcid.org/0000-0003-2398-1254)
Claudiu T. Supuran [http://orcid.org/0000-0003-4262-0323](http://orcid.org/0000-0003-4262-0323)

**References**

1. a) Lovisolo PP, Briatico-Vangosa G, Orsini G, et al. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity. Pharmacol Res Commun 1981;13:163–74. b) Fuccella LM, Goldaniga G, Lovisolo P, et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 1980;28:790–5.

2. a) Stirling C, McAleer M, Reckless JP, et al. Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 1985;68:83–8. b) Singh A, Faccenda D, Campanella M. Pharmacological advances in mitochondrial therapy. EBioMedicine 2021;65:103244. c) Lintott CJ, Scott RS, Bremer JM. Treatment of hyperlipidaemia with acipimox. Curr Med Res Opin 1989;11:374–9.

3. a) Locci Cubeddu T, Masiello P, Pollera M, Bergamini E. Effects of antilipolytic agents on rat liver peroxisomes and peroxisomal oxidative activities. Biochim Biophys Acta 1985; 839:96–104. b) Bergamini E. Searching for the fountain of autophagy-dependent youth: Ettore Bergamini. Interview by Daniel J. Klionsky. Autophagy 2012;8:1169–74.

4. a) Cavallini G, Donati A, Bergamini E. Antiaging therapy: a novel target for antilipolytic drugs. Mini Rev Med Chem 2014;14:551–6. b) Cavallini G, Donati A, Taddei M, Bergamini E. Peroxisomes proliferation and pharmacological stimulation of autophagy in rat liver: evidence to support that...
autophagy may remove the "older" peroxisomes. Mol Cell Biochem 2017;431:97–102.

5. a) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95. b) Cadoni R, Pala N, Lomelino C, et al. Exploring heteroaryl-pyrazole carboxylic acids as human carbonic anhydrase XII inhibitors. ACS Med Chem Lett 2017;8:941–6. c) Langella E, D’Ambrosio K, D’Ascenzo M, et al. A combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes in the active site of carbonic anhydrases. Chemistry 2016;22:97–100. d) Cvijetić IN, Tânc M, Juranić IO, et al. 5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII. Bioorg Med Chem 2015;23:4649–59.

6. Annunziato G, Angeli A, D’Alba F, et al. Discovery of new potential anti-infective compounds based on carbonic anhydrase inhibitors by rational target-focused repurposing approaches. ChemMedChem 2016;11:1904–14.

7. a) Cau Y, Vullo D, Mori M, et al. Potent and selective carboxylic acid inhibitors of tumor-associated carbonic anhydrases IX and XII. Molecules 2017;23:17. b) Cau Y, Mori M, Supuran CT, Botta M. Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. Org Biomol Chem 2016;14:8322–30. c) Mori M, Cau Y, Vignaroli G, et al. Hit recycling: discovery of a potent carbonic anhydrase inhibitor by in silico target fishing. ACS Chem Biol 2015;10:1964–9.

8. a) Supuran CT. Carbonic anhydrase inhibitors: designing iso-enzyme-specific inhibitors as therapeutic agents. In: Chegwidden WR, Carter ND, eds. The carbonic anhydrases: current and emerging therapeutic targets. Cham: Springer International Publishing; 2021: p. 221–235; b) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80. c) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60. d) Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.

9. a) Supuran CT. Novel carbonic anhydrase inhibitors. Future Med Chem 2021;13:1935–7. b) Briganti P, Pierattelli R, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10. c) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32. d) Rotondo G, Guglielmi P, Carradori S, et al. Design, synthesis and biological activity of selective hCA s inhibitors based on 2-(benzylsulfinyl)benzoic acid scaffold. J Enzyme Inhib Med Chem 2019;34:1400–13.

10. a) D’Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun 2015;51:302–5. b) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med Res Rev 2020;40:2485–565. c) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81. d) Alhameed RA, Berrino E, Almarhoon Z, et al. A class of carbonic anhydrase IX/XII -selective carboxylate inhibitors. J Enzyme Inhib Med Chem 2020;35:549–54.

11. a) Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020; 12:603–17. b) Winum JY, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445–63. c) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond) 2021;135:1233–49. d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77. e) Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2021;30:1197–208. a) Angeli A, Carta F, Nocentini A, et al. Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. Metabolites 2020;10:412. b) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 - 2013). Expert Opin Ther Pat 2013;23:681–91. c) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12. d) Mincone F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 2021;16:1209–25. e) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.

12. a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016; 16:961–8. b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebro ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9. c) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isofoms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3. d) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60: 1159–70. e) Dettori I, Fusco I, Bulli I, et al. Protective effects of carbonic anhydrase inhibition in brain ischaemia in vitro and in vivo models. J Enzyme Inhib Med Chem 2021,36: 964–76.

13. a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016; 16:961–8. b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebro ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9. c) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isofoms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3. d) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60: 1159–70. e) Dettori I, Fusco I, Bulli I, et al. Protective effects of carbonic anhydrase inhibition in brain ischaemia in vitro and in vivo models. J Enzyme Inhib Med Chem 2021,36: 964–76.

14. Bozdag M, Ferraroni M, Ward C, et al. Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells. Eur J Med Chem 2019;182:116000.

15. Behnke CA, Le Trong I, Godden JW, et al. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr D Biol Crystallogr 2010;66:616–27.

16. Elder I, Fisher Z, Laipis PJ, et al. Structural and kinetic analysis of proton shuttle resides in the active site of human carbonic anhydrase III. Proteins 2007;68:337–43.

17. Vernier W, Chong W, Rewolinski D, et al. Thioether benzene-sulfonamide inhibitors of carbonic anhydrases II and IV: Structure-based drug design, synthesis, and biological evaluation. Bioorg Med Chem 2010;18:3307–19.

18. Pilka ES, Kochan G, Oppermann U, Yue WW. Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor
development. Biochem Biophys Res Commun 2012;419:485–9.

19. Buemi MR, Di Fiore A, De Luca L, et al. Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety. Eur J Med Chem 2019;163:443–52.

20. Leitans J, Kazaks A, Balode A, et al. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem 2015;58:9004–9.

21. Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001;98:9545–50.

22. Di Fiore A, Monti SM, Hilvo M, et al. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins 2009;74:164–75.

23. La Regina G, Coluccia A, Famiglini V, et al. Discovery of 1,1-biphenyl-4-sulfonamides as a new class of potent and selective carbonic anhydrase XIV inhibitors. J Med Chem 2015;58:8564–72.

24. Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 16 Rev. C.01. Wallingford, CT, 2016.

25. Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using GOLD. Proteins 2003;52:609–23.

26. Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.

27. Case DA, Cheatham TE, 3rd, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88.

28. Maier JA, Martinez C, Kasavajhala K, et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 2015;11:3696–713.

29. Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem 2004;25:1157–74.

30. Kuchlyan J, Martinez-Fernandez L, Mori M, et al. What makes thienoguanosine an outstanding fluorescent DNA probe? J Am Chem Soc 2020;142:16999–7014.

31. Ciaco S, Humbert N, Real E, et al. A class of potent inhibitors of the HIV-1 nucleocapsid protein based on aminopyrrolic scaffolds. Acs Med Chem Lett 2020;11:698–705.

32. Ballone A, Picarazzi F, Prosser C, et al. Experimental and computational druggability exploration of the 14-3-3-\(\text{SOS1p}\) S1161 PPI interface. J Chem Inf Model 2020;60:6555–65.

33. Dragoii F, Bocutto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res 2020;175:104708.

34. Roe DR, Cheatham TE. 3rd. PTRAJ and CPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 2013;9:3084–95.

35. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.

36. a) Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869–73. b) Vullo D, Voipio J, Innocenti A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cystolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2005;15:971–6. c) Gieling RG, Babur M, Mannani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 2012;55:5591–600. d) Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem 2014;6:1149–65.

37. a) Sarikaya SB, Gülcin I, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids. Chem Biol Drug Des 2010;75:515–20. b) Yi I, Rö m A, Atmaca U, Keskin A, et al. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. Bioorg Med Chem 2015;23:2598–605. c) Innocenti A, Gülcin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isozymes I-XV. Bioorg Med Chem Lett 2010;20:5050–3.

38. a) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31. b) Oztürk Sarikaya SB, Topal F, Sentürk M, et al. In vitro inhibition of \(\alpha\)-carbonic anhydrase isozymes by some phenolic compounds. Bioorg Med Chem Lett 2011;21:4259–62.

39. a) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2010;15:671–86. b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88. c) De Simone G, Alteori V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 2013;8:793–810.

40. Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev 2006;26:531–68.

41. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.